Form 4: Protara CEO Shefferman Boosts Stake with New Equity Awards

Protara Therapeutics CEO and President Jesse Shefferman received significant equity awards, including 87,000 restricted stock units and options for 524,000 shares, effective January 16, 2026.

Summary

• Jesse Shefferman, CEO and President of Protara Therapeutics, Inc. (TARA), acquired 87,000 shares of common stock through Restricted Stock Unit (RSU) awards.
• These RSUs vest in equal one-third installments on the first, second, and third anniversaries of January 16, 2026, contingent on continuous service.
• Shefferman also acquired stock options to purchase 524,000 shares of common stock with an exercise price of $5.01 per share.
• The stock options begin vesting with 25% on the one-year anniversary of January 16, 2026, and 1/48th of the shares vesting monthly thereafter over the subsequent three years, also subject to continuous service.
• The stock options have an expiration date of January 15, 2036.
• Following these transactions, Shefferman beneficially owns 1,046,886 shares of common stock and 524,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports significant equity awards to the CEO, which is generally positive as it aligns management's incentives with shareholder value. However, it is a compensation event rather than a direct operational or financial performance indicator.

Positives

• The significant equity awards to the CEO and President, Jesse Shefferman, align management's long-term interests with those of shareholders.
• The awards demonstrate a commitment from key leadership, potentially signaling confidence in the company's future performance.

Negatives

• The awards are compensation and do not represent an immediate cash investment by the CEO into the company's stock.
• The vesting schedules mean the full beneficial ownership is not immediate and is contingent on continued employment.

Risks

• The vesting of both the Restricted Stock Units and stock options is subject to the Reporting Person's continuous service with the Issuer, meaning the awards could be forfeited if employment ceases before vesting.

Future Outlook

The future outlook indicates a structured vesting schedule for significant equity awards over the next one to three years, contingent on the CEO's continuous service. This suggests a long-term incentive structure for executive leadership.

Industry Context

Equity-based compensation, such as restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent. These awards are designed to align the interests of management with those of shareholders by tying compensation to the company's stock performance.

Comparison to Industry Standards

• The use of RSUs and stock options for executive compensation is a common practice across the biotech and pharmaceutical sectors, aligning with typical industry standards for long-term incentive plans.
• The specific grant amounts and vesting schedules would require a detailed comparison to peer companies of similar market capitalization and development stage to assess their relative size and structure.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's financial interests with the company's long-term stock performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Vesting of 87,000 Restricted Stock Units in equal one-third installments on the first, second, and third anniversaries of January 16, 2026.
• Vesting of 524,000 stock options, with 25% vesting on the one-year anniversary of January 16, 2026, and 1/48th monthly thereafter over the next three years.

Key Dates

Keywords

Protara Therapeutics, TARA, Jesse Shefferman, SEC Form 4, insider transaction, equity awards, restricted stock units, stock options, CEO compensation, corporate governance